AbbVie’s Humira recommended for hidradenitis suppurativa approval in Europe

AbbVie has announced that its drug Humira has been recommended for European regulatory approval in the treatment of hidradenitis suppurativa.

The Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for Humira to be approved in the treatment of active moderate to severe hidradenitis suppurativa in adolescents from 12 years of age who have seen an inadequate response to conventional therapy.

Hidradenitis suppurativa is sometimes referred to as acne inversa and is a painful, debilitating, chronic inflammatory skin disease estimated to affect one to four percent of the world's population.

If approved, Humira would become the first and only biologic treatment option for patients aged 12 years and older with this disease.

John Medich, vice-president for immunology clinical development at AbbVie, said: "This positive CHMP opinion is a significant milestone for patients impacted by this painful, chronic disease, as there are currently no approved medications available for adolescents to treat it."

Humira was approved for adults with moderate to severe hidradenitis suppurativa by the European Commission in July 2015.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.